The six scientists are conducting basic and tumor immunology laboratory investigations at distinguished academic institutions throughout the United States, as well as in Greece and Japan. Areas of research under investigation within the investigators’ laboratories include immune cell signaling pathways, immuno-modulation and regulatory mechanisms, and genetic factors of immune cell development and function.
The CRI Investigator Award Program aids scientists who are newly embarking on their independent academic research careers at the assistant professor level. These awards are not tied to any specific research project. Rather, the awards provide researchers the freedom to pursue promising lines of inquiry that their new responsibilities otherwise might not allow them to follow. The aim of the program is to provide flexibility and a degree of stability in what is essentially a make-or-break period in the scientist’s life. Since the Investigator Award Program’s inception in 1986, 120 investigators have received funding from the Cancer Research Institute, including the newest winners.
June 2008 Investigator Award Recipients
• Hongbo Chi, Ph.D., at St. Jude Children’s Research Hospital, Memphis, Tennessee, is investigating how the MAPK protein pathway, a pathway essential for integrating signals from antigen and cytokine receptors, functions in dendritic cell-mediated immune responses and stimulation of anti-tumor immunity. His study may be translated into new therapeutic strategies for treating cancers and autoimmune diseases.
• Morgan Huse, Ph.D., at the Memorial Sloan-Kettering Cancer Center, New York, New York, is studying how natural killer cells receive inhibitory and activating signals to induce natural killing responses to cancerous cells. Developing an understanding of natural killer cell mechanisms advances strategies to modulate their activity to better fight cancer.
• Hiroyoshi Nishikawa, M.D., Ph.D., at the University Graduate School of Medicine, Tsu, Mie, Japan, is clarifying questions of how regulatory T cells (Tregs) suppress immune responses by identifying which antigens are recognized by Tregs. This knowledge would provide an important next step to avoid undesired activation of Tregs by cancer vaccines aimed at inducing CD4+ Th helper cell-dependent development of antibodies.
• Neetu Gupta, Ph.D., at the Cleveland Clinic Foundation, Cleveland, Ohio, is enhancing the current understanding of B-cell activation, a process critical to antibody production. She is studying a protein called ezrin, which facilitates the B-cell response by participating in signal communication. Ultimately, this research promises a better comprehension of immunological diseases that result from interruption of signaling pathways and cellular architecture, and would enable identification of drug targets for specific and smarter therapy.
• Charalampos Spilianakis, Ph.D., at the Foundation of Research and Technology – Hellas (FORTH), Crete, Greece, is characterizing the protein complexes that generate and/or maintain interchromosomal interactions to understand how the genome is shaped and how the nuclear structure affects global gene expression. His research could lead to new insight into the link between the physical proximity of genomic loci and the increased probability of chromosomal translocations (mutations) and how these can lead to the creation of cancerous malignancies.
• Russell E. Vance, Ph.D., at the University of California, Berkeley, Berkeley, California, is addressing the fundamental question of how the immune system initially distinguishes normal from abnormal tissue by studying how a gene called Naip5 regulates the innate immune response. This understanding could help develop Naip5-related therapeutics that will stimulate innate immune responses against pathogenic intruders or tumors in cases when the immune system has inappropriately ignored these dangers.
More detailed descriptions of the investigators’ research can be viewed at http://www.cancerresearch.org/programs/research/investigator-award/investigators-2008-06.html. CRI extends its congratulations to each of this year’s award recipients. The next deadline for Investigator Award applications is March 1, 2009.About the Cancer Research Institute
The Cancer Research Institute has one of the lowest overhead expense ratios among non-profit organizations, with the majority of its resources going directly to the support of its science, medical, and research programs. This has consistently earned CRI an A grade or higher for fiscal disclosure and efficiency from the American Institute of Philanthropy and top marks from other charity watchdog organizations. http://www.cancerresearch.org
Brian Brewer | Newswise Science News
Helmholtz International Fellow Award for Sarah Amalia Teichmann
20.01.2017 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt
Scientist from Kiel University coordinates Million Euros Project in Inflammation Research
19.01.2017 | Christian-Albrechts-Universität zu Kiel
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
20.01.2017 | Awards Funding
20.01.2017 | Materials Sciences
20.01.2017 | Life Sciences